StockData

MediciNova vs Yarrow Bioscience

MNOV and YARW side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MNOV and YARW compare

MediciNova is the larger company, worth 1.8 times as much as Yarrow Bioscience ($66.0M against $37.2M).

MediciNova keeps more of each dollar of sales as profit, with a net margin of −1168% compared with −4646% at Yarrow Bioscience.

Yarrow Bioscience pays a dividend yielding 144%; MediciNova does not pay one.

Yarrow Bioscience scores higher on the StockData Score (11 against 7 for MediciNova), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMNOVYARW
Size and price
Market cap$66.0M$37.2M
Share price$1.34$13.93
Change, 1 year−13.0%−24.6%
Change, 5 years−58.4%−98.5%
Beta (5Y)−0.002.09
Employees610
StockData Score
Total score711 (better)
Valuation score11
Growth score01 (better)
Performance score11
Health score55
Dividend score03 (better)
Valuation
P/S71.7×65.2× (better)
P/B1.8×1.7× (better)
FCF yield−13.8% (better)−89.1%
Fair value–$6.94
Margin of safety–−101%
Growth
Revenue growth (TTM)–13.8%
Revenue growth, 5Y average–−51.4%
Profitability
Operating margin−1287% (better)−5219%
Net margin−1168% (better)−4646%
FCF margin−991% (better)−5811%
Return on equity−25.6% (better)−86.9%
Return on invested capital−76.6%–
Financial health
Debt / equity0.000.00
Current ratio8.7515.26 (better)
Altman Z-score−3.11 (better)−33.88
Piotroski F-score23 (better)
Dividends and buybacks
Dividend yield–144%
Shareholder yield0.00%144% (better)
Ownership
Held by institutions10.5%11.6%
Held by insiders12.8%82.1%
Insider net buying, 12 months−$1.7M–
Short interest, % of float0.66%29.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.